Ecolab Inc 's (ECL) Outlook - CSIMarket
CSIMarket
 
Ecolab Inc   (NYSE: ECL)
 



  Ecolab Inc Outlook

On February 11 2025 the Ecolab Inc provided following guidance

nnEcolab Inc. Projects Robust Financial Growth for 2025 Following a Record-Setting 2024 Performancenn

On February 11, 2025, Ecolab Inc. announced impressive results for its fourth quarter and a remarkable overall performance for the fiscal year 2024. The company's reported diluted earnings per share (EPS) reached $1.66, while the adjusted diluted EPS climbed to $1.81, reflecting a notable increase of 17% year-over-year. This strong upward trajectory in earnings showcases Ecolab's sustained momentum and operational excellence.

Looking ahead, Ecolab has provided an optimistic outlook for 2025, projecting its adjusted diluted EPS to range between $7.42 and $7.62. This anticipated figure represents an encouraging growth forecast of 12% to 15%, underscoring the company's confidence in its strategic initiatives and market positioning.

nnKey Highlights from Q4 Performance:nn
Based in St. Paul, Minnesota, Ecolab reported fourth-quarter sales totaling $4.0 billion, marking a 2% increase compared to the previous year. The company's organic sales grew by 4%, driven largely by accelerated growth in its Industrial and Healthcare and Life Sciences segments. Additionally, the Pest Elimination and Institutional and Specialty segments continued to show robust performance.

Regionally, the United States demonstrated particularly strong organic sales growth. Meanwhile, other global markets also contributed positively, with new business acquisitions significantly outweighing any potential downturns.

Overall, Ecolab's strong finish in 2024, combined with its positive financial outlook for 2025, positions the company for ongoing success in the years to come.,

On October 29 2024 the Ecolab Inc provided following guidance

Ecolab Inc. recently reported robust financial performance for the third quarter, with a reported diluted earnings per share (EPS) of $2.58. More notably, the adjusted diluted EPS was $1.83, reflecting a significant increase of 19% year-over-year. As a result of this strong performance, the company has revised its outlook for adjusted diluted EPS in 2024 to a target range of $6.60 to $6.70, indicating a year-over-year growth of approximately 27% to 29%.

In their press release from St. Paul, Minnesota, Ecolab (NYSE: ECL) highlighted several key metrics from the third quarter. The company reported total sales of $4.0 billion, marking a slight increase of 1% compared to the previous year. This figure was impacted by a 2% decrease related to the divestiture of the global surgical solutions business and an additional 1% decline stemming from foreign currency exchange fluctuations. However, on an organic basis, Ecolab saw a healthy growth rate of 4%, demonstrating strong performance across various business segments.

Ecolab also reported a notable acceleration in volume growth, which increased by 2%, fueled by successful new business acquisitions and innovative product breakthroughs. The company successfully maintained its pricing strategy, achieving value pricing within the targeted range of 2-3%, aided by strong relationships with customers.

Overall, these results underscore Ecolab's commitment to sustained growth and operational excellence, positioning itself favorably for continued success in the upcoming year.,

On February 13 2024 the Ecolab Inc provided following guidance

Ecolab Inc. announced strong performance in the fourth quarter, with reported diluted earnings per share (EPS) of $1.41 and adjusted diluted EPS of $1.55, showing a 22% increase. The company also provided a positive outlook for 2024, with projected adjusted diluted EPS in the range of $6.10 to $6.50, reflecting a 17% to 25% growth.

In the fourth quarter, Ecolab reported sales of $3.9 billion, representing a 7% increase compared to the previous year. The company achieved organic sales growth of 6%, driven by double-digit growth in the Institutional and Specialty segment and Pest Elimination, as well as solid growth in the Industrial segment. The Healthcare and Life Sciences segment maintained stable sales compared to the previous year but showed strong sequential sales growth.

Additionally, Ecolab reported a 48% increase in reported operating income and a 21% increase in organic operating income. This growth was primarily attributed to improved cost management and operational efficiency.

Overall, Ecolab's strong performance in the fourth quarter and positive outlook for 2024 indicate the company's continued growth and success in the market.





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.